Johnson & Johnson

With over 40 million viewers, 20 categories and dozens of nominees, this massive ceremony is only glitz and glamour on the surface. Corporate titans are investing tirelessly behind the scenes to make this all possible. Not to be outdone by Sochi's top Olympic ad prices, the cost of this year's...

U.S. stocks rose on Friday as investors were able to overlook some disappointing economic data as a result of cold weather. Major indices showed signs of strength today as the Nasdaq continues to inch towards historical all time highs of 5,135.52 recorded on March 10,2000. Today, the index hit...

U.S. stocks rose on Thursday as investors and traders focused on the positives. Data showed that the economy expanded in the fourth quarter as consumer spending gained traction. "Today the market is focused on the good news, or the developed world," Bill Stone, chief investment strategist at...

Markets ended the day mixed with the S&P 500 ending a two day losing streak. The Dow ended the day slightly in the negative as several Dow components failed to fully satisfy investor expectations with their earnings today. Investors also digested the latest commentary coming from the Wall...

On Tuesday morning, Johnson & Johnson (NYSE: JNJ) reported its fourth quarter results. The company announced an EPS of $1.24, beating the consensus estimate by four cents. Revenue of $18.40 billion came in $450 million higher than the consensus estimate. The company benefited from domestic...

The markets are closed on Monday for Martin Luther King Day, but after that the earnings season shifts back into high gear. The consensus forecasts for eBay, McDonald's, Netflix, Starbucks and Verizon call for year-over-year growth in per-share earnings. But analysts are looking for declining...

Major indices reversed Monday's losses and posted strong gains following a better than expected retail sales report and a luke-warm start to earnings season. Related: Stocks Higher, But Dollar Indecisive After Retail Sales Release Philidalphia's Fed chief Charles Plosser said that he wants QE...

Alcoa may have reported disappointing results last week, but the fourth-quarter earnings season really kicks off this week with reports from J.P. Morgan (NYSE: JPM) and Wells Fargo (NYSE: WFC) on Tuesday. Big name financials will be well represented this week, with results due from the likes of...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

Markets were relatively calm during Thursday's trading session as investors anticipate Friday's jobs report. The December employment report is expected to show about 200,000 payroll jobs representing a steady growth and a clear sign that labor market and economy are both strong. Related:...

For the first time in the new year, markets ended the day on a positive note. While it is only a few days in, markets appear to have started off 2014 on uncertain footing. Investors and traders found some positives in the U.S. trade deficit which fell to its lowest level in four years, an...

This weekend in Barron's online: a special report on the outlook for 2014. Also, the prospects for eBay, YPF, Innophos Holdings and more. Cover Story "An Upbeat View of 2014" by Vito J. Racanelli. After the crazy ride of the past six years, Wall Street analysts see things settling down to normal...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...

The third-quarter earnings crunch is underway this week. The financial sector will be well represented, with quarterly reports due from the likes of Goldman Sachs and American Express, as well as the tech sector, highlighted by Google and Intel. Coca-Cola and Johnson & Johnson are among the...

Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...